For the quarter ended March 2025, Heron Therapeutics (HRTX) reported revenue of $38.9 million, up 12.2% over the same period last year. EPS came in at $0.01, compared to -$0.02 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $37.08 million, representing a surprise of +4.93%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being -$0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call May 06, 2025 08:00 AM ET Company Participants Melissa Jarel - Executive Director - LegalCraig Collard - CEO & DirectorIra Duarte - Executive VP & CFOClara Dong - Vice President - Biotechnology Equity ResearchCarl Byrnes - Managing Director Conference Call Participants Serge Belanger - Senior Analyst Operator Good day, and thank you for standing by. Welcome to the Heron Therapeutics Q1 twenty twenty five Conference Call. At this time, all participants are i ...

Q1 2025 Earnings Call Heron Therapeutics May 6, 2025 Forward-looking Statements and Non-GAAP Disclosures This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date hereof and are subject to certain risks and uncertainties that could cause actual results to differ materially. Examples of forward-looking statements include, ...

Generated Q1 2025 Net Revenue of $38.9 million Delivered record Q1 2025 Adjusted EBITDA of $6.2 million Reached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032 Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today anno ...

— Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 —CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related t ...